Retinal Photocoagulation Laser Market Global Report 2026

The retinal photocoagulation laser market size has grown rapidly in recent years. It will grow from $4.27 billion in 2025 to $4.82 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to rising prevalence of diabetic retinopathy and retinal disorders, increasing adoption of laser based ophthalmic treatments, growth in ophthalmology infrastructure and eye care clinics, advancements in medical laser technology, expansion of minimally invasive surgical procedures.

The retinal photocoagulation laser market size is expected to see rapid growth in the next few years. It will grow to $7.69 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to integration of AI in ophthalmic diagnostics and treatment planning, rising demand for outpatient retinal procedures, growing geriatric population with vision disorders, increasing adoption of precision laser therapies, expansion of healthcare access in emerging economies. Major trends in the forecast period include AI assisted retinal laser treatment planning systems enabling precision targeting of retinal lesions and improved clinical outcomes, image guided laser photocoagulation systems integrated with optical coherence tomography for real time retinal mapping, micropulse laser therapy adoption for reduced retinal tissue damage and faster patient recovery, portable and minimally invasive retinal laser devices enabling outpatient and ambulatory care expansion, advanced multicolor laser systems improving treatment precision across multiple retinal disease types.

The rising prevalence of retinal diseases is anticipated to drive the growth of the retinal photocoagulation laser market in the coming years. Retinal diseases are ocular disorders that impact the retina, the light-sensitive layer at the back of the eye that plays a critical role in vision, and include conditions such as diabetic retinopathy, age-related macular degeneration, glaucoma, and rhegmatogenous retinal detachment. The occurrence of retinal diseases is increasing due to the rapid aging of the global population, along with the growing prevalence of chronic conditions such as diabetes that contribute to the development and progression of retinal disorders. Retinal photocoagulation laser therapy manages various retinal diseases by applying concentrated laser energy to seal leaking blood vessels, inhibit the growth of abnormal blood vessels, and slow disease progression before permanent vision impairment occurs. For instance, in July 2025, according to the Office for Health Improvement and Disparities, a UK-based government agency, during the financial year ending 2024, England reported 13,129 hospital admissions for rhegmatogenous retinal detachment surgery, corresponding to a rate of 27.5 (26.9-28.0) per 100,000 population, which increased from the previous financial year’s rate of 25.9 per 100,000 population. Therefore, the growing prevalence of retinal diseases is contributing to the expansion of the retinal photocoagulation laser market.

Major companies operating in the retinal photocoagulation laser market are focusing on the development of advanced technologies, such as tissue-sparing retinal laser systems, to enhance treatment accuracy, minimize unintended retinal damage, and improve patient outcomes. Tissue-sparing retinal laser systems are advanced ophthalmic laser technologies designed to selectively treat affected retinal areas while limiting thermal damage to adjacent healthy retinal tissues. For example, in April 2023, IRIDEX Corporation, a US-based ophthalmic laser technology company, introduced the next-generation PASCAL laser platform integrated with MicroPulse technology. The platform combines pattern-scanning laser delivery with tissue-preserving micropulse treatment capabilities, provides customizable treatment settings for greater procedural adaptability, and enables efficient retinal treatment through advanced laser pattern technology. These capabilities allow ophthalmologists to perform more precise retinal procedures while reducing thermal effects on healthy retinal structures. Therefore, advancements in micropulse laser technology are contributing to the growth of the retinal photocoagulation laser market by enabling more accurate, tissue-preserving, and clinically effective retinal treatments.

In April 2026, IRIDEX Corporation, a US-based ophthalmic laser technology company, partnered with EyeProGPO to expand access to its retinal laser treatment technologies across ophthalmology practices and ambulatory surgical centers in the United States. The partnership is intended to strengthen the market reach of IRIDEX’s retinal photocoagulation laser portfolio, including PASCAL, IQ 532, IQ 577, and OcuLight TX laser platforms, while enhancing provider access to advanced retinal treatment solutions. EyeProGPO is a US-based ophthalmology-focused group purchasing organization that offers procurement support, technology access, and operational services to eye care practices.

Major companies operating in the retinal photocoagulation laser market report are Carl Zeiss Meditec AG, Alcon Inc., Bausch & Lomb Incorporated, Topcon Corporation, Lumenis Be Ltd., Appasamy Associates Private Limited, Lumibird Medical Group, LIGHTMED Corporation, Iridex Corporation, NIDEK Co. Ltd., OD-OS GmbH, Modulight Corporation, Haag-Streit UK Limited, Aurolab, Lab Medica Systems Private Limited, Norlase ApS, Salient Medical Solutions Inc., SIMTRUM Pte. Ltd., Chongqing Vision Star Optical Co. Ltd., Nanjing Redsun Optical Co. Ltd., Keeler Limited, Nocitech, Suzhou Kangjie Medical Inc.

North America was the dominating region in the retinal photocoagulation laser market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the retinal photocoagulation laser market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the retinal photocoagulation laser market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.